Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist.
Anticancer Res
; 25(1A): 197-206, 2005.
Article
in En
| MEDLINE
| ID: mdl-15816539
ABSTRACT
BACKGROUND:
Angiogenesis is a complex process involving endothelial cell migration, proliferation, invasion, and tube formation. Inhibition of these processes might have implications in various angiogenesis-mediated disorders. MATERIALS ANDMETHODS:
The antiangiogenic efficacy of the novel alphavbeta3 antagonist TA138 was examined using in vivo and in vitro model systems.RESULTS:
The in vitro studies demonstrated the ability of TA138 and RP747 (conjugated TA138) to inhibit endothelial cell migration toward vitronectin, with an IC50=0.04 and 0.045 microM, respectively. Furthermore, utilizing the chick chorioallantoic membrane models, TA138 inhibited basic fibroblast growth factor-induced neovascularization.CONCLUSION:
TA138 might be a useful tool for the inhibition of angiogenesis associated with human tumor growth, or other pathological neovascularization processes. RP747 demonstrated antitumor efficacy in 1 spontaneous tumor model (c-neu oncomouse model, alphavbeta3 positive cells) and in 1 xenograft model (HCT116 human tumor colon carcinoma, alphavbeta3 negative cells) injected subcutaneously into nude mice.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Sulfonamides
/
Adenocarcinoma
/
Colonic Neoplasms
/
Angiogenesis Inhibitors
/
Integrin alphaVbeta3
/
Heterocyclic Compounds, 1-Ring
/
Mammary Neoplasms, Experimental
Type of study:
Prognostic_studies
Limits:
Animals
/
Female
/
Humans
Language:
En
Journal:
Anticancer Res
Year:
2005
Document type:
Article
Affiliation country:
United States